Nano Labs Announces Annual General Meeting

Nano Labs Announces Annual General Meeting GlobeNewswire December 02, 2025 HONG KONG, Dec. 02, 2025 (GLOBE NEWSWIRE) — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading Web 3.0 infrastructure and product solution provider, today announced that it will hold its 2025 Annual General Meeting of Shareholders (the “2025 Annual Meeting”) […]

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation GlobeNewswire December 02, 2025 Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN

NevGold Intercepts Highest-Grade Oxide Antimony At Bullet Zone Discovery: 5.51% Antimony Over 4.6 Meters Within 4.00 g/t AuEq Over 41.1 Meters (0.96% Antimony And 0.29 g/t Au) at Limo Butte, Nevada

NevGold Intercepts Highest-Grade Oxide Antimony At Bullet Zone Discovery: 5.51% Antimony Over 4.6 Meters Within 4.00 g/t AuEq Over 41.1 Meters (0.96% Antimony And 0.29 g/t Au) at Limo Butte, Nevada GlobeNewswire December 02, 2025 Vancouver, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company“) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased

Village Farms International Reaffirms its Commitment to the Texas Cannabis Industry

Village Farms International Reaffirms its Commitment to the Texas Cannabis Industry GlobeNewswire December 02, 2025 Outcome of conditional license awards has zero impact on Company's financial performance, outlook or strategy Company believes that its operating capabilities and infrastructure are well suited to support a viable industry in Texas MARFA, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE)

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer GlobeNewswire December 02, 2025 NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer.

Next Hydrogen Solutions Inc. Announces Change of Auditor

Next Hydrogen Solutions Inc. Announces Change of Auditor GlobeNewswire December 02, 2025 MISSISSAUGA, Ontario, Dec. 02, 2025 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (TSXV: NXH, OTC: NXHSF) (“Next Hydrogen” or the “Company“), announces that it has changed its auditor from KPMG LLP (“Former Auditor“) to MNP LLP (“Successor Auditor“). The Former Auditor resigned at

Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia

Comanche Biopharma Appoints Richard Colvin, MD, PhD as Global Head of R&D and John McHutchison, AO, MD as Chairman and Director of Comanche Biopharma Australia GlobeNewswire December 02, 2025 Deeply experienced industry leaders further strengthen Comanche's leadership and expertise as it advances CBP-4888 as a potential global solution for sFlt1-mediated preterm preeclampsia CONCORD, Mass., Dec.

Rocky Shore Strengthens Its Gold Anchor Project by Adding Two Significant Historical Gold Resources

Rocky Shore Strengthens Its Gold Anchor Project by Adding Two Significant Historical Gold Resources GlobeNewswire December 02, 2025 TORONTO, Dec. 02, 2025 (GLOBE NEWSWIRE) — Rocky Shore Gold Ltd. (“Rocky Shore” or the “Company“) (CSE: RSG) is pleased to announce that, through a wholly-owned subsidiary, it has entered into an option agreement and a purchase

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita(R) Procedure

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita(R) Procedure GlobeNewswire December 02, 2025 Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment 1.5% mean weight change observed with Revita (n=17); published

Scroll to Top